DESIGNED TO DELIVER 71% Target Lesion Primary Patency*
The COVERA™ Vascular Covered Stent utilizes a
unique, helical design intended to balance the flexibility and strength required for tortuous outflow anatomy of the venous anastomosis. In fact, the AVeVA Clinical Study demonstrated a 71% target lesion primary patency rate at 6 months.*
The COVERA™ Vascular Covered Stent is
built upon proven technologies from the category leader in AV Access.
To find out more about how the COVERA™ Vascular
Covered Stent was designed to help you deliver results, visit
www.bardpv.com.
T71%
arget Lesion Primary Patency*
*Target Lesion Primary Patency (TLPP) of 71%, defined as the interval following the index intervention until the next clinically-driven reintervention at or adjacent to the original treatment site or until the extremity was abandoned for permanent access. Freedom from primary safety events = 96.4%, defined as freedom from any adverse events, localized or systemic, that reasonably suggests the involvement of the AV access circuit (not including stenosis or thrombosis) that require or result in any of the following alone or in combination: additional interventions (including surgery); in-patient hospitalization or prolongation of an existing hospitalization; or death. AVeVA Clinical Study. Data on File. Bard Peripheral Vascular Inc., Tempe AZ
Please consult product labels and package inserts for indications, contraindications, hazards, warnings, cautions, and information for use. © 2018 BD. BD, the BD logo and all other trademarks are property of Becton, Dickinson and Company. Illustrations by Mike Austin. All Rights Reserved. Bard Peripheral Vascular, Inc. |
www.bardpv.com | 1 800 321 4254 | 1625 W. 3rd Street Tempe, AZ 85281 BPV/SGF2/0818/0135
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40
